SGLT2 作用机制 SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) 治疗领域 内分泌与代谢疾病 在研适应症 2型糖尿病 非在研适应症 原发性高血压 原研机构 Theracos, Inc. 在研机构 恒翼生物医药(上海)股份有限公司Piramal Healthcare UK Ltd.Theracos, Inc. ...
钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在治疗2型糖尿病中的有效性和安全性重点
but it can also be the consequence of it [3]. This underscores the importance of optimal diabetes control in patients with HF. Although there is a multitude of efficacious medications for T2DM, they do not appear to reduce the risk of cardiovascular (CV) outcomes ...
this study did not control for changes in background antihypertensive medications, a large limitation to the study results.19 The initial reduction in blood pressure seen with SGLT2 inhibitor use is believed to be due to the osmotic diuresis effects from inhibition of renal glucose and sodium...
Analysis from the Empa-Reg Outcome((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int. 2019;96(2):489–504. 14. Wanner C, Inzucchi SE, ...
lowering medications (combined GLP-1 RAs, DPP-4 inhibitors, or gliclazide;P = 0.049) [111]. Mechanisms of renal benefits with SGLT2 inhibitors The inhibition of SGLT2 leads to tubuloglomerular feedback via enhanced natriuresis and delivery of sodium to the macula densa, thereby decreasing ...
Nevertheless, some undesirable adverse effects caused by the administration of these medications, including hypoglycemia, gastrointestinal symptoms, weight gain, and hepato-renal toxicity, have increased demand for the discovery of safer antidiabetic agents with novel therapeutic mechanisms [3]. After the ...
Current oral medications for type 2 diabetes target a single main physiological mechanism. They either activate or inhibit receptors to enhance insulin sensitivity, increase insulin secretion, inhibit glucose absorption, or inhibit glucose production. In advanced stages, combination therapy may be required...